Harnessing Interactive DTC to Drive Demand in Product Launch
Given the importance of a rapid launch of new products, many pharmaceutical firms are turning to consumer marketing tools to create consumer demand. To date, much of the consumer marketing effort has focused on direct-to-consumer advertising, but more and more drug companies are learning to harness the power of the Internet to push out their product message.Far more than simply establishing a web site, interactive DTC--or iDTC--marketing is a two-way approach whereby companies and consumers exchange information through feedback loops, the end result of which is to develop and deepen customer relationships. To be effective, however, iDTC campaigns must have a clear sense of the bottlenecks to product adoption, establish reasonable goals and expectations, and coordinate with and complement much more traditional launch strategies.
by Michele Holcomb, Ana Gupte, and Vijay Iyengar
With so much riding on a successful blockbuster launch, pharmaceutical companies are turning to all available tools to achieve rapid...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.